Latest news
- Business13 October 2021
CellResearch Corporation has been awarded an Innovation Passport for CorLiCyte™
Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), has been awarded an Innovation Passport for CorLiCyte™, by the UK’s regulatory agencies (MHRA, NICE, SMC), becoming one of...
- Business07 October 2021
Adalvo announces successful DCP submission for Lisdexamfetamine Oral Solution
Adalvo is delighted to announce the successful submission of our DCP procedure for Lisdexamfetamine Oral Solution 10mg / ml which has been developed in close collaboration with Laboserve & Pharma-Data....
- Business28 September 2021
Adalvo announces successful DCP closure for Icatibant
Adalvo is pleased to announce the successful closure on our DCP procedure for our Icatibant development, a complex injectable peptide product, forming part of our high-value product portfolio offering to...
- Business14 September 2021
Adalvo announces successful DCP filing for Teriflunomide
Adalvo is pleased to announce the successful DCP filing on its Teriflunomide development, a new addition to our high-value product portfolio offering to our partners.
- Business26 August 2021
Adalvo announces successful Pivotal BE outcome of Lisdexamfetamine Oral Solution 10mg / ml
Adalvo is delighted to announce the successful Pivotal BE outcome of its Lisdexamfetamine Oral Solution 10mg / mlwhich has been developed in close collaboration with Laboserve & Pharma-Data.
- Business18 August 2021
Adalvo announces completion of Phase III patient enrollment for Dimethyl Fumarate 30 mg / 120 mg
Adalvo is pleased to announce that we have completed our patient enrollment of our Phase 3 clinical study, to assess the safety and efficacy of Dimethyl Fumarate 30 mg /...
- Business05 August 2021
Adalvo and Hansoh Pharma enter into an exclusive license partnership
Adalvo and Jiangsu Hansoh Pharma, a leading R&D-driven pharmaceutical company in China, are pleased to announce that they have entered into an strategic partnership for the commercialization of Fulvestrant pre-filled injection...
- Business29 July 2021
Lotus Enhanced Oncology Pipeline
Adalvo is the only B2B platform with a real selected boutique approach to portfolio. We are proud to offer products from all the major pharmaceutical domains, oncology being one of...
- Business19 July 2021
Adalvo submits dossier application for Enzalutamide Soft Gel Capsule 40mg
Adalvo is pleased to announce that following the successful compilation of all necessary requirements, we have submitted our dossier for Enzalutamide, and did proceed for filing via several DCP procedures...
- Business12 July 2021
Adalvo submits generic dossier application for Dimethyl Fumarate hard capsules
Adalvo is pleased to announce that in light of the most recent General Court decision that revoked data exclusivity protection on Dimethyl Fumarate (Tecfidera®) hard capsules, we have submitted our...
- Business21 June 2021
Teduglutide - A Unique Opportunity With Vast Orphan Market Potential
Adalvo is very excited about this unique opportunity with vast orphan market potential
- Business11 June 2021
Adalvo announces successful pivotal BE trial outcome of Lisdexamfetamine development
Adalvo is delighted to announce the successful Pivotal BE outcome of its Lisdexamfetamine hard capsules development which demonstrates Adalvo´s ability to continuously offer first-to-market opportunities to its valued partners.
- Business07 May 2021
Adalvo announces DCP filing of Solifenacin+Tamsulosin MR tablets
Adalvo is happy to announce that following the successful compilation of all necessary requirements today we submitted our Solifenacin+Tamsulosin MR Tablet dossier and will proceed via several DCP procedures in...
- Business31 March 2021
We are pleased to share our exciting DCP schedule for 2021
Here at Adalvo we are committed to being always on target with the aim of achieving great results for our partners and patients.
- Business23 March 2021
Adalvo announces ready-to-file dossier completion on Pomalidomide hard capsules development
Adalvo is delighted to announce the completion of an eCTD format dossier on our Pomalidomide hard capsules development.
- Business18 January 2021
Adalvo announces successful Pivotal BE trial on Teriflunomide development
Adalvo is happy to claim positive pivotal PK result on its Teriflunomide development which will soon be a new addition to our high-value product portfolio to our customers.
- Business04 January 2021
Adalvo announces successful pivotal BE trial outcome of Drospirenone + Estradiol program
We are happy to announce a positive pivotal PK outcome of our Drospirenone + Estradiol development which is our new milestone in creating Adalvo’s mission for a boutique portfolio containing...
- Business14 December 2020
Are you feeling the holiday buzz?
As the Holidays are rapidly approaching, we really wanted to take this opportunity to thank you all for your wonderful collaboration and support in what has undoubtedly been a truly...
- Business05 November 2020
Adalvo wins Business Development of the Year award at the annual Global Generics Awards
The Adalvo team have certainly been busy bees this year, driven by their passion for relentless commitment to customers and business partners. Adalvo has been a true success story...
- Business30 October 2020
Adalvo announces completion on BE trials of Solifenacin + Tamsulosin development
Adalvo is happy to announce that in addition to our earlier reported studies we successfully closed our last bioequivalence trial that was conducted in steady state dosing.
- Business05 August 2020
Alvotech and Teva announce strategic partnership to collaborate in the U.S. biosimilar market
Alvotech and Teva bring together highly complementary capabilities to secure a leading position in the U.S. biosimilar market. The collaboration is one of the broadest partnerships within the U.S. biosimilar...